The role of PET/CT in the evaluation of patients with urothelial cancer: a systematic review and meta-analysis
The aim of our systematic review and meta-analysis is to define the role of PET/CT in the evaluation of patients with urothelial cancer (UC).
Searches of the major scientific literature databases were carried out to select English language articles dealing with PET and UC. Only original articles concerning UC patients who were (1) candidates for radical surgery, (2) restaged for suspicions of recurrences or metastasis and (3) evaluated after treatments were selected and included in the present study. Abstract, reviews, clinical cases and editor comments were excluded. Moreover, articles on the optimization of PET/CT study protocol, such as refilling, diuretic administration or similar, were excluded. Only studies that met the following criteria were included in the meta-analysis: sample size equal to/greater than 15 patients; index test: 18F-FDG PET/CT; standard of reference for the identification of disease; outcomes, such as true positive, true negative, false positive and false negative, which allowed us to construct 2 × 2 contingency tables.
Thirty-three papers were collected and analyzed. The studies included a total of 1944 patients, of which 1661 patients were assessed at initial staging and 283 in the restaging phase. 18F-FDG was the most employed tracer for the evaluation of UC patients (29 out of 33 studies), while 11C-choline and 11C-acetate were employed alone or in concomitance in three and one articles, respectively. The pooled sensitivities and specificities of 18F-FDG PET/CT were 41.8% (95% CI 41.1–52.5), 91% (95% CI 88.2–93.3), 94% (95% CI 88.6–97.4) and 93% (95% CI 84.3–97.7), respectively, for lymph node involvement at the initial staging and in the restaging phase. Both in initial staging and in restaging, 18F-FDG PET/CT was more accurate than conventional imaging (i.e., CT and/or MRI).
18F-FDG PET/CT is more accurate than conventional imaging for the evaluation of patients with UCs, both in the staging and in the restaging setting. In this latter phase, 18F-FDG PET/CT has a high pooled diagnostic performance. A multicenter study should be drawn to demonstrate how PET/CT imaging is useful in the diagnostic pathway of patients with UCs.
KeywordsUrothelial cancer FDG PET/CT Bladder cancer Upper tract urinary cancer Meta-analysis
The authors are thankful to Christina Drace for the English language editing.
ARC and LC: literature search and review, and manuscript writing; PR: content planning; MB: manuscript writing; GS: content planning and manuscript editing; LE: meta-analysis, content planning and manuscript editing.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interests.
Research involving human participants and/or animals
Informed consent was not necessary for the present study.
- 1.Romain M et al (2015) Upper urinary tract disease: what we know today and unmet needs. Transl Androl Urol 4:261–272Google Scholar
- 5.Secin FP et al (2007) Evaluation of regional lymph node dissection in patients with upper urinary tract. Urol 14:26–32Google Scholar
- 7.Vind-Kezunovic S, Bouchelouche K, Ipsen P, Høyer S, Bell C, Bjerggaard Jensen J (2017) Detection of lymph node metastasis in patients with bladder cancer using maximum standardised uptake value and 18F-fluorodeoxyglucose positron emission tomography/computed tomography: results from a high-volume centre including long-term follow-up. Eur Urol Focus. https://doi.org/10.1016/j.euf.2017.06.005
- 9.Soubra A, Hayward D, Dahm P, Goldfarb R, Froehlich J, Jha G, Konety B (2016) The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis. World J Urol 34:1229–1237CrossRefPubMedGoogle Scholar
- 10.European Association of Urology (EAU), http://uroweb.org/. Accessed Sept 2017
- 11.American Urological Association (AUA), http://www.auanet.org/. Accessed Sept 2017
- 13.www.nccn.org. Accessed Sept 2017.
- 20.Maurer T, Souvatzoglou M, Kubler H, Opercan K, Schmidt S, Herrmann K, Stollfuss J, Weirich G, Haller B, Gschwend JE, Schwaiger M, Krause BJ, Treiber U (2012) Diagnostic efficacy of [11C] choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy. Eur Urol 61(5):1031–1038CrossRefPubMedGoogle Scholar
- 25.Mertens LS, Mir MC, Scott MS, Ting Lee S, Fioole-Bruining A, Vegt E, Vogel WV, Manecksha R, Bolton D, Davis ID, Horenblas S, Van Rhijn BWG, Lawrentschuk N (2014) 18F-fluorodeoxyglucosee positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer. Urology 83:398–399CrossRefGoogle Scholar
- 26.Sassa N, Kato K, Abe S, Iwano S, Ito S, Ikeda M, Shimamoto K, Yamamoto S, Yamamoto T, Gotoh M, Naganawa S (2014) Evaluation of 11C-choline PET/CT for primary diagnosis and staging of urothelial carcinoma of the upper urinary tract: a pilot study. Eur J Nucl Med Mol Imaging 41:2232–2241CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Kollberg P, Almquist H, Bläckberg M, Cronberg C, Garpered S, Gudjonsson S, Kleist J, Lyttkens K, Patschan O, Liedberg F (2015) [18F] Fluorodeoxyglucose—positron emission tomography/computed tomography improves staging in patients with high-risk muscle-invasive bladder cancer scheduled for radical cystectomy. Scand J Urol 49:296–301CrossRefPubMedGoogle Scholar
- 29.Asai S, Fukumoto T, Tanji N, Miura N, Miyagawa M, Nishimura K, Yanagihara Y, Shirato A, Miyauchi Y, Kikugawa T, Yokoyama M (2015) Fluorodeoxyglucose positron emission tomography/computed tomography for diagnosis of upper urinary tract urothelial carcinoma. Int J Clin Oncol 20:1042–1047CrossRefPubMedGoogle Scholar
- 30.Tanaka H, Yoshida S, Komai Y, Sakai Y, Urakami S, Yuasa T, Yamamoto S, Masuda H, Koizumi M, Kohno A, Fukui I, Yonese J, Fujii Y, Kihara K (2016) Clinical value of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography in upper tract urothelial carcinoma: impact on detection of metastases and patient management. Urol Int 96:65–72CrossRefPubMedGoogle Scholar
- 36.Giannatempo P, Alessi A, Miceli R, Raggi D, Farè E, Nicolai N, Serafini G, Padovano B, Piva L, Biasoni D, Torelli T, Catanzaro M, Stagni S, Maffezzini M, Mariani L, Gianni AM, Sonpavde G, Salvioni R, Necchi A, Crippa F (2014) Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma. Clin Genitourin Cancer 12:433–439CrossRefPubMedGoogle Scholar
- 43.Kibel AS, Dehdashti F, Katz MD, Klim AP, Grubb RL, Humphrey PA, Siegel C, Cao D, Gao F, Siegel BA (2009) Prospective study of [18F] fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 27(26):4314–4320CrossRefPubMedPubMedCentralGoogle Scholar
- 45.Jensen TK, Holt P, Gerke O, Riehmann M, Svolgaard B, Marcussen N, Bouchelouche K (2011) Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology. Scand J Urol Nephrol 45(2):122–128CrossRefPubMedGoogle Scholar
- 46.Hitier-Berthault M, Ansquer C, Branchereau J, Renaudin K, Bodere F, Bouchot O, Rigaud J (2013) 18F-fluorodeoxyglucose positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: a prospective study. Int J Urol 20:788–796CrossRefPubMedGoogle Scholar